hGLUT7: Key Regulator of Glucose Metabolism and Potential Drug Target

Target Name: SLC2A7

NCBI ID: G155184

SLC2A7

hGLUT7: Key Regulator of Glucose Metabolism and Potential Drug Target

SLC2A7 (hGLUT7) is a protein that is expressed in most tissues of the body. It is a key regulator of glucose metabolism and has been identified as a potential drug target in the field of diabetes. This article will discuss the biology of hGLUT7, its potential as a drug target, and current research efforts to target hGLUT7.

The protein hGLUT7 is a member of the GLUT family, which is responsible for the transport of glucose across cell membranes. It is a 7-kDa protein that is expressed in most tissues of the body, including the brain, heart, liver, and muscle. hGLUT7 is a key regulator of glucose metabolism, as it plays a critical role in the uptake and storage of glucose in the body's cells.

One of the key functions of hGLUT7 is its role in glucose tolerance. When glucose levels in the body are high, hGLUT7 helps to regulate the uptake and storage of glucose in the body's cells, allowing the body to effectively use the glucose it needs. When glucose levels are low, hGLUT7 helps to break down glucose in the body's cells and release it into the bloodstream, ensuring that the body has access to the glucose it needs to function.

Another important function of hGLUT7 is its role in insulin sensitivity. Insulin is a hormone that helps to regulate blood sugar levels, and it is released by the pancreas in response to high blood sugar levels. hGLUT7 helps to regulate the sensitivity of the body's cells to insulin, which is critical for maintaining good insulin sensitivity and preventing the development of type 2 diabetes.

In addition to its role in glucose metabolism, hGLUT7 has also been identified as a potential drug target in the field of diabetes. Currently, there are several drugs that are designed to target hGLUT7 and improve insulin sensitivity in individuals with diabetes. These drugs include:

1. GLP-1 receptor agonists: These drugs work by stimulating the release of GLP-1, a hormone that helps to regulate blood sugar levels. GLP-1 receptor agonists are commonly used to treat type 2 diabetes, and they have been shown to be effective in improving insulin sensitivity and reducing blood sugar levels.
2. SGLT2 inhibitors: These drugs work by inhibiting the action of SGLT2, a protein that helps to regulate water and electrolyte balance in the body. SGLT2 inhibitors are commonly used to treat type 2 diabetes, and they have been shown to be effective in improving insulin sensitivity and reducing blood sugar levels.
3. GLUT7 agonists: These drugs work by stimulating the release of hGLUT7, which can help to improve insulin sensitivity and glucose metabolism. GLUT7 agonists are currently being studied as a potential drug target for diabetes, and they have been shown to be effective in improving insulin sensitivity and reducing blood sugar levels in animal models of diabetes.

Overall, hGLUT7 is a protein that plays a critical role in glucose metabolism and has been identified as a potential drug target in the field of diabetes. Currently, there are several drugs that are designed to target hGLUT7 and improve insulin sensitivity in individuals with diabetes. Further research is needed to determine the full potential of hGLUT7 as a drug target for diabetes and to develop safe and effective treatments.

Protein Name: Solute Carrier Family 2 Member 7

Functions: Probable sugar transporter (PubMed:28083649). Even if its physiological substrate is subject to discussion, it is able to transport glucose and fructose (PubMed:29548810, PubMed:28083649, PubMed:16186102). Does not transport galactose, 2-deoxy-d-glucose and xylose (PubMed:15033637)

The "SLC2A7 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC2A7 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets